Catalog No.A2011 Synonyms: SAR153191, REGN88 Non-humanized mouse model applicable
For research use only. Not for use in humans.
Sarilumab (anti-IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD.
Choose Selective IL Receptor Inhibitors
|Description||Sarilumab (anti-IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD.|
Sarilumab (SAR153191/REGN88) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity thereby blocking cis and trans IL-6-mediated inflammatory signalling cascade, and with no evidence of complement-dependent or antibody-dependent cell-mediated cytotoxicity. Sarilumab provides partial growth inhibition of a subset of the tumor cell lines tested, e.g., DU145 (prostate), Calu3 (lung) and A549 (lung). Sarilumab bound with high affinity to recombinant monomeric human and monkey IL-6 receptor with a KD value of 61.9 pM and 71.9 pM, respectively. The binding affinity of sarilumab to the dimeric human IL-6 receptor Fc-fusion is 12.8 pM. sarilumab is specific to human and monkey IL-6 receptor and does not cross-react with mouse IL-6R.
|In vivo||Sarilumab has been shown in preclinical studies to inhibit IL-6 signalling in a dose-dependent manner.|
|Formulation||PBS buffer, pH 7.2|
|Storage||Store at -80°C and avoid freeze-thaw cycles.|
If you have any other enquiries, please leave a message.